Irradiation Dose to the Swallowing Muscles Impacts Nutritional Status in Head and Neck Cancer Patients: The Prospective Randomized HEADNUT Trial

PURPOSE/OBJECTIVE(S)

To evaluate the influence of radiation dose on swallowing muscles and associated side effects as well as on nutritional status in patients with head and neck cancer undergoing primary or adjuvant (chemo)radiotherapy.

MATERIALS/METHODS

Between 2018 and 2020, sixty-one patients were prospectively randomized into the so-called HEADNUT-trial (HEAD and neck cancer patients undergoing NUTritional intervention). Follow-up was continued until 2022. Contouring of the swallowing apparatus included and the swallowing muscles with the superior (scm), middle (mcm), and inferior constrictor muscle (icm), the cricopharyngeal muscle and the inlet of the esophagus. Nutritional status was assessed by bioelectrical impedance analysis (BIA) at the beginning and the end of radiotherapy. The post-therapeutic nutritional status was evaluated by the BIA-derived FFMI (fat-free mass index; kg/m²). Malnutrition was assumed at FFMI values of <15 (♀) and <17 (♂) kg/m². To find differences between dosimetric parameters in well- and malnourished patients, Mann-Whitney-U-test was used. To estimate the relationship between malnutrition and its influencing variables a logistic regression model was built.

RESULTS

The following structures differed between well- and malnourished patients at the end of therapy: icm (Dmean, V40Gy (%), V50Gy (%), V60Gy (%)) and cricopharyngeal muscle (V40Gy (%)). After entering these parameters into a multivariable logistic regression model icm Dmean (b = -0.12; Exp(b) = 0.88; 95%-CI: 0.78-1.0; p = 0.06) and icm V40Gy (%) (b = 0.06; Exp(b) = 1.07; 95%-CI: 1-1.13; p = 0.04) proved to be independent predictors of malnutrition. We only determined the cut-off value for icm V40Gy (%) since it was the only parameter which met p<0.05. The optimal cut-off value for the predictor V40Gy (%) based on the Youden Index was 85.6%.

CONCLUSION

Adherence to dose constraints for the swallowing apparatus may prevent malnutrition in head and neck cancer patients at the end of therapy. Specifically, we suggest an icm V40Gy (%) of more than 86% being predictive for nutritional complications.

Xerostomia after radiotherapy. What matters--mean total dose or dose to each parotid gland?

PURPOSE

Xerostomia is a debilitating side effect of radiotherapy in patients with head and neck cancer. We undertook a prospective study of the effect on xerostomia and outcomes of sparing one or both parotid glands during radiotherapy for patients with squamous cell carcinoma of the head and neck.

METHODS AND MATERIALS

Patients with locally advanced squamous cell carcinoma of the head and neck received definitive (70 Gy in 2 Gy fractions) or adjuvant (60-66 Gy in 2 Gy fractions) curative-intent radiotherapy using helical tomotherapy with concurrent chemotherapy if appropriate. Group A received < 26 Gy to the left and right parotids and group B received < 26 Gy to either parotid.

RESULTS

The study included 126 patients; 114 (55 in group A and 59 in group B) had follow-up data. There were no statistically significant differences between groups in disease stage. Xerostomia was significantly reduced in group A vs. group B (p = 0.0381). Patients in group A also had significantly less dysphagia. Relapse-free and overall survival were not compromised in group A: 2-year relapse-free survival was 86% vs. 72% in group B (p = 0.361); 2-year overall survival was 88% and 76%, respectively (p = 0.251).

CONCLUSION

This analysis suggests that reducing radiotherapy doses to both parotid glands to < 26 Gy can reduce xerostomia and dysphagia significantly without compromising survival. Sparing both parotids while maintaining target volume coverage and clinical outcome should be the treatment goal and reporting radiotherapy doses delivered to the individual parotids should be standard practice.

Leptomeningeal metastases: Results of different therapeutic approaches

2047

Background: The aim of this study was to compare different treatment options for patients with leptomeningeal metastases (LM). Method: In this retrospective single center study all patients (n=135) between 1985 and 2005 diagnosed with leptomeningeal metastases (LM) showing malignant cells in the cerebrospinal fluid (CSF) were evaluated. Results: 135 patients, 80 females and 55 males, were treated for LM, 73 patients with solid tumors and 62 patients with hematological malignancies. Of the total 135 patients 28% received combined chemotherapy and intrathecal chemotherapy (ITC), 22% only ITC, 3% received only systemic chemotherapy, 28.5% radiochemotherapy and 1.5% radiotherapy only. 13% patients were treated with supportive therapy only and in 4% therapy could not be evaluated. Median overall survival (OS) was 2.5 months (3 days- 58.2 months). According to univariate analysis age > 50 years and Karnofsky status < 80 were predictors of poor survival. Response to therapy and application of systemic therapy were correlated with longer survival. In this study, time of survival varied considerably depending on the type of primary tumor. Univariate analysis of Kaplan-Meier plots revealed age >50 years and Karnofsky performance status <80 as therapy-independent predictors of poor survival. Positive prognostic factors were response to therapy as measured by malignant cell count in the CSF, and application of systemic chemotherapy alone or in combination with other therapy-modalities in the entire cohort. Difference through systemic therapy was extremely relevant for the two entities NHL (n=37) and breast cancer (BC) (n=35). The median OS was 4.4 months for NHL and 7.0 months for BC following systemic therapy compared to 1.8 months for NHL and 1.4 months for BC without systemic treatment thus demonstrating a significant better OS using systemic therapy. Conclusion: The results suggest that systemic chemotherapy has the main impact on improved survival in patients with LM and chemosensitive disease. Still the prognosis for patients with LM is poor and treatment is aimed at palliation of symptoms and preservation of neurologic function. Future randomized studies of therapies should include quality-of-life assessment and provide additional data on this important outcome.

No significant financial relationships to disclose.

Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation

We report the results of 84 patients with ALL after related (n = 46) or unrelated (n = 38) allogeneic SCT. Mean recipient age was 23 years (range: 1-60) and median follow-up was 18 months (range: 1-133). Forty-three patients were transplanted in CR1; 25 in CR2 or CR3; four were primary refractory; four in PR; eight in relapse. The conditioning regimen consisted of TBI/VP16/CY (n = 76), TBI/VP16 (n = 2), TBI/CY (n = 2), Bu/VP16/CY (n = 4). The OS at 3 years was 45% (44% unrelated, 46% related). Univariate analysis showed a significantly better OS for patients <18 years (P=0.03), mismatched sex-combination (P = 0.03), both with a stronger effect on increasing OS after unrelated SCT. Factors decreasing TRM were patient age <18 years (P = 0.004), patient CMV-seronegativity (P = 0.014), female recipient (P = 0.04). There was no significant difference in TRM and the relapse rate was similar in both donor type groups. Multivariate analysis showed that factors for increased OS which remained significant were mismatched sex-combination (RR: 0.70,95% CI: 0.51-0.93, P = 0.015), patient age < 18 years (RR: 0.66, 95% CI: 0.47-0.93, P = 0.016). A decreased TRM was found for female patients (RR: 0.56, 95% CI: 0.33-0.98, P=0.042), negative CMV status of the patient (RR: 0.57, 95% CI: 0.36-0.90, P = 0.015). Unrelated stem cell transplantation for high-risk ALL patients with no HLA-compatible family donor is justifiable.